<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441919</url>
  </required_header>
  <id_info>
    <org_study_id>NL62200.091.17</org_study_id>
    <nct_id>NCT03441919</nct_id>
  </id_info>
  <brief_title>Activation Innate Immune System in Type 1 Diabetes</brief_title>
  <official_title>Activation of the Innate Immune System and Vascular Inflammation in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperglycemia is a well-known cardiovascular risk factor. It has also been shown that&#xD;
      episodes of hyperglycemia increase the risk for cardiovascular diseases despite return to&#xD;
      normoglycemia, a phenomenon termed 'glycemic or metabolic memory'. The molecular mechanism&#xD;
      underlying this phenomenon remains unclear.&#xD;
&#xD;
      Cardiovascular events, such as myocardial infarction and stroke are caused by&#xD;
      atherosclerosis, which is characterized by low grade inflammation of the vascular wall,&#xD;
      including accumulation of innate immune cells such as monocytes and macrophages.&#xD;
&#xD;
      The investigators hypothesize that chronic hyperglycemia shifts intracellular metabolism of&#xD;
      innate immune cells towards glycolysis and changes the epigenetic state of (progenitors of)&#xD;
      innate immune cells (monocytes and macrophages), which reprograms these cells towards a more&#xD;
      aggressive, pro-atherogenic phenotype, thereby accelerating atherosclerosis.&#xD;
&#xD;
      In this study, the investigators aim to test this hypothesis. This research will reveal&#xD;
      whether the innate immune cells of patients with chronic hyperglycemia show a durable shift&#xD;
      in intracellular metabolism and epigenetic changes and whether this associates with vascular&#xD;
      inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Actual">January 21, 2019</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial wall inflammation, measured by 18F-FDG-PET/CT</measure>
    <time_frame>through study completion, within 1 year</time_frame>
    <description>Compare arterial wall inflammation (expressed as target-to-background-ratio (TBR) measured in large arterial vessels) between well- and poorly-controlled patients. The TBR is the ratio of FDG uptake in large arterial and large venous bloodvessels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FDG (fluorodeoxyglucose) uptake in spleen and bone marrow, measured by 18F-FDG-PET/CT.</measure>
    <time_frame>through study completion, within 1 year</time_frame>
    <description>Measurement of FDG uptake in bone marrow and spleen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory phenotype</measure>
    <time_frame>Most measurements within 1 week after inclusion. Cytokine measurements after completion of the inclusion of all patients.</time_frame>
    <description>Blood will be collected for all subjects. LPS induced TNF production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular metabolism, measured by Seahorse respirometer</measure>
    <time_frame>within 1 day after inclusion</time_frame>
    <description>Measurement of mitochondrial stress test = oxygen consumption rate (OCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes</measure>
    <time_frame>Within 2 months after inclusion</time_frame>
    <description>Measurement of epigenetic changes by ChIP-seq (chromatin immunoprecipitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial wall inflammation, measured by 18F-FDG-PET/CT</measure>
    <time_frame>through study completion, within 1 year</time_frame>
    <description>Compare arterial wall inflammation between diabetes patients and healthy subjects. Comparison by using TBR (see description Outcome 1).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">66</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Innate Immune System</condition>
  <condition>Inflammation</condition>
  <condition>Metabolism Disorder, Glucose</condition>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes, poor glycemic control</arm_group_label>
    <description>Diagnosis based on clinical criteria&#xD;
Duration of diabetes ≥10 years&#xD;
Age ≥20 years, ≤ 60 years&#xD;
HbA1c &gt;64 mmol/mol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes, good glycemic control</arm_group_label>
    <description>Diagnosis based on clinical criteria&#xD;
Duration of diabetes ≥10 years&#xD;
Age ≥20 years, ≤ 60 years&#xD;
HbA1c &lt;64 mmol/mol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Absence of disease, no use of medication&#xD;
Matched for age, gender and BMI&#xD;
HbA1c &lt;42 mmol/mol</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET-CT (positron emission tomography - computer tomography)</intervention_name>
    <description>PET-CT to determine vascular inflammation</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with type 1 diabetes, good glycemic control</arm_group_label>
    <arm_group_label>Patients with type 1 diabetes, poor glycemic control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood drawn</intervention_name>
    <description>Blood drawn</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with type 1 diabetes, good glycemic control</arm_group_label>
    <arm_group_label>Patients with type 1 diabetes, poor glycemic control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 1 diabetes patients, without macrovascular complications. Minimum diabetes duration 10&#xD;
        years.&#xD;
&#xD;
        Patients are recruited at university hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group 1 and 2 (patients with type 1 diabetes):&#xD;
&#xD;
          -  Diagnosis based on clinical criteria&#xD;
&#xD;
          -  Duration of diabetes ≥10 years&#xD;
&#xD;
          -  Age ≥20 years, ≤ 60 years&#xD;
&#xD;
          -  Group 1: HbA1c &gt;64 mmol/mol&#xD;
&#xD;
          -  Group 2: HbA1c ≤64 mmol/mol&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Group 3 (healthy controls):&#xD;
&#xD;
          -  Absence of disease, no use of medication&#xD;
&#xD;
          -  Matched for age, gender and BMI&#xD;
&#xD;
          -  HbA1c &lt;42 mmol/mol&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Specific Medication use:&#xD;
&#xD;
               -  Use of immunosuppressive drugs&#xD;
&#xD;
               -  Use of statins &lt; 2 weeks before performing PET-CT (Those that use statins will be&#xD;
                  asked to discontinue for two weeks. This can be safely done in the context of&#xD;
                  primary prevention.)&#xD;
&#xD;
               -  Use of acetylsalicylic acid&#xD;
&#xD;
          -  Previous cardiovascular events (ischemic stroke/TIA (transient ischemic attack),&#xD;
             myocardial infarction, peripheral arterial disease)&#xD;
&#xD;
          -  Auto-inflammatory or auto-immune diseases&#xD;
&#xD;
          -  Current or recent infection (&lt; 3 months)&#xD;
&#xD;
          -  Previous vaccination (&lt; 3 months)&#xD;
&#xD;
          -  Renal failure (MDRD &lt;45)&#xD;
&#xD;
          -  BMI&gt;30 kg/m2&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Severe hypoglycaemia &lt; 1 week before PET-CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre, Department of Internal Medicine</name>
      <address>
        <city>Nijmegen</city>
        <zip>PO BOX 9101, 6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

